Jinfang Pharmaceutical-B (02595) announced interim results with net loss of 220 million yuan, narrowing by 68.48% year-on-year

According to the Zhitong Finance App, Jingfang Pharmaceutical-B (02595) announced interim results for the six months ended June 30, 2026, with revenue of 42.473 million yuan (RMB, same below), a year-on-year decrease of 52.14%; R&D expenses of 193 million yuan, an increase of 57.25%; net loss of 220 million yuan, a year-on-year narrowing of 68.48%; and a basic loss of 0.59 yuan per share.

According to the announcement, in the first six months of this year (as of June 30), the company's revenue exceeded RMB 42 million, of which drug supply revenue increased nearly 6 times, demonstrating the potential for clinical development of the company's pipeline products at home and abroad, as well as the company's integrated development capabilities; other revenue and revenue exceeded RMB 40 million. Cash and bank balances (including cash and cash equivalents, restricted bank deposits, and term deposits with an initial term exceeding three months) exceeded RMB 1,784 billion on June 30 this year.